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Abstract. Pancreatic cancer is one of the leading causes of
cancer death, and represents a challenging chemotherapeutic
problem. The crucial role of angiogenesis in tumor growth
has been widely recognized, and several reports have
revealed that the combination treatment of the conventional
chemotherapeutic drugs and anti-angiogenic agents exerted
synergistic anti-cancerous effects. It has been reported that
the clinically used angiotensin type-1 receptor blocker (ARB)
exerted potent anti-angiogenic activity. The aim of our
current study was to examine the combination effect of
gemcitabine (GEM), a widely used conventional chemothera-
peutic drug against pancreas cancer, and losartan (Lo), an
ARB, on murine pancreatic tumor growth, especially in
conjunction with angiogenesis. When used individually,
GEM and Lo at clinically comparable low doses moderately
suppressed pancreatic tumor development. The combination
treatment with GEM and Lo exerted a marked inhibitory
effect as compared with single agent treatments even after
the tumor was fully established. Neovascularization and the
expression of the vascular endothelial growth factor (VEGF),
a central angiogenic factor, in the tumor were both markedly
suppressed in a magnitude similar to the inhibitory effects
against the tumor growth. Since both agents are widely used
in the clinical practice, the combination regimen of GEM
and Lo may represent a potential new therapeutic strategy for
pancreatic cancer in the future.
Introduction
Exocrine pancreatic carcinoma is now the fifth leading cause
of cancer in Japan, United States and Europe, with an overall
5-year survival rate of less than 5% (1). The majority of
patients are potential candidates for systemic treatment
because the tumor is already unresectable at the time of
diagnosis due to metastasis or the presence of locally advanced
disease (2). Since 1997, gemcitabine (GEM) has been used
for patients with advanced pancreatic cancer (3). Although
GEM exerted a modest anti-tumor activity, it could achieve a
significant improvement in the disease-related symptoms and
prolong the survival of advanced pancreatic cancer patients.
GEM produces a response rate of only 12-27% with a median
survival of only 4-6 months, and it frequently induces drug
resistance like most of the other conventional chemo-
therapeutic agents (3-5). New therapeutic approaches based
on the biologic characteristics of this disease are required
to improve the response rates and survival of patients with
advanced pancreatic cancer.
It is now widely recognized that the growth of any solid
tumor depends on angiogenesis. Without angiogenesis, the
tumor ceases to grow even beyond a few millimeters in size;
i.e., ‘tumor dormancy’ (6). Since inhibition of angiogenesis is
now considered as a promising approach for cancer therapy,
the efforts are currently directed worldwide at overcoming
tumor angiogenesis (7). Although angiography in the clinical
practice revealed that most pancreatic cancers are hypovascular
or avascular, the human pancreatic cancer cells reportedly
overexpress pro-angiogenic molecules such as the vascular
endothelial growth factor (VEGF), a central key pro-angiogenic
factor (8). In patients with pancreatic cancer, the intra-
tumoral microvessel density proved to be an independent
prognostic factor for survival in multivariate analysis (9,10).
Furthermore, in animal models, the anti-angiogenic
compounds have proven very successful in inhibiting
pancreatic tumor development (11-14). Collectively, angio-
genesis also plays a pivotal role in the growth of pancreatic
tumors.
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It has been reported that combination treatments of anti-
angiogenic agents and the conventional chemotherapeutic
drugs at low doses exert a more potent inhibitory effect on
tumor development than single-agent treatment (15). Since a
long-term administration is required for anti-angiogenic
treatment, selection of safe agents is necessary.
Angiotensin-II (AT-II) is an octapeptide produced mainly
via proteolytic cleavage of its precursor angiotensin-I by
angiotensin-converting enzyme (ACE), and is mainly coupled
with angiotensin type-1 receptor (AT1-R). ACE inhibitor
(ACE-I) and AT1-R blocker (ARB), that block the AT-II
biological activities, are widely used as anti-hypertensive
agents without serious side effects in the clinical practice.
Several investigators including our group have shown that
ACE-I and ARB possess strong anti-angiogenic activity, and
that these agents could inhibit the growth of several types of
tumors at clinically comparable low doses (16,17). AT-II
reportedly plays an important role in angiogenesis of
pancreatic cancer through VEGF (18). Furthermore, it has
been reported that ARB suppressed the growth of human
pancreatic cancer cells in vitro (19).
In the current study, to evaluate the possible feasibility of
future clinical application, we examined the combination
effect of GEM and losartan (Lo), an ARB, at clinically com-
parable low doses on the murine pancreatic tumor develop-
ment and angiogenesis, and we investigated the possible
mechanisms involved.
Materials and methods
Compounds and cell lines. GEM and Lo were generously
supplied by Eli Lilly Japan K.K. (Hyogo, Japan) and Banyu
Pharmaceutical Co., Ltd. (Tokyo, Japan), respectively. The
murine pancreatic cancer cell line, Pan02 (National Cancer
Institute, Frederick, MD), was cultured in RPMI-1640 medium
(Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10%
(v/v) fetal bovine serum, 1% ampicillin/streptomycin, and
1% glutamine. The cells were grown in the media recom-
mended by the respective suppliers.
Animal treatment. A total of 40 male 6-week-old C57BL/6
mice were purchased from Japan SLC, Inc. (Hamamatsu,
Shizuoka, Japan). They were housed under controlled
temperature conditions and relative humidity, with 10-15 air
changes per hour (h) and light illumination for 12 h a day. To
create the allograft model, 2.5x105 Pan02 cells were injected
into the flank of C57BL/6 mice. After the tumor was fully
established (the mean tumor volume was 200 mm3 on day 21),
the mice were randomly divided into four groups (n=10 in
each group). Group 1 (G1) consisted of untreated mice that
served as a control group. Mice in G2 and G3 received GEM
(50 mg/kg) twice a week via intraperitoneal injection and
Lo (30 mg/kg/day) in the drinking water, respectively. The
concentration of Lo in the drinking water was adjusted
according to the water intake to maintain a constant daily
dose of the drug. The doses of these agents in the current
study were almost comparable to those used in the clinical
practice (20,21). To examine the combination effect of GEM
and Lo, Lo was additionally administered to GEM group
on day 49 (G4). The animals were allowed free access to
food and water throughout the acclimation and experiment
protocols. The tumor volume was measured twice a week, and
the mice were sacrificed on day 73 after tumor cell implant-
ation. All animal procedures were performed according to
approved protocols and in accordance with the recommen-
dations for the proper care and use of laboratory animals.
Immunohistochemistry. For determination of the in vivo
angiogenesis, we employed immunohistochemical detection
of platelet/EC adhesion molecule (PECAM/CD31), which is
widely used as a marker of neovascularization, in frozen
sections of tumors with the same size to avoid the necrotic
effect of hypoxia as described previously (22). The immuno-
stained microvessel length was assessed under x200-fold
magnification. In each tumor sample, five areas showing the
highest density of staining were selected for counting. In
counting, the large vessels with a thick muscular wall or with
a lumen >50 μm in diameter were excluded. These immuno-
positive vessels were evaluated with Adobe Photoshop and
NIH image software as described previously (23).
Measurement of the VEGF expression in tumors. We measured
the VEGF protein expression level in the tumor. Because
different sizes of the tumor may cause different hypoxic
conditions, which strongly induce VEGF (24), five tumors
having the same size were chosen from each group. The
tumor samples were prepared as described previously (16).
After the protein concentration was equalized, the VEGF
level was measured with an ELISA kit (R&D Systems,
Minneapolis, MN, USA) in accordance with the supplier's
instructions.
Statistical analysis. To assess the statistical significance of
inter-group differences in the quantitative data, Bonferroni's
multiple comparison test was performed after one-way
ANOVA. This was followed by Barlett's test to determine the
homology of variance.
Results
Effect of GEM and Lo on tumor development. We first
examined the effect of clinically comparable doses of GEM
and Lo on the pancreatic tumor development. As shown in
Fig. 1, single agent treatment with either GEM (G2) or Lo
(G3) showed moderate inhibitory effect on the pancreatic
tumor development as compared to the control group (G1)
(p<0.05, each). The inhibitory effect in G2 and G3 were
almost of similar magnitude. Mice treated with GEM plus Lo
(G4) showed a significant inhibition of the tumor volume as
compared with those of G2 or G3 and G1 (p<0.05 and <0.01,
respectively). The current doses of both agents did not affect
the health status, such as body weights during the experiment
in all experimental groups (data not shown).
Tumor neovascularization. To determine whether the
inhibitory effect of GEM and Lo on the tumor development
was accompanied by suppression of neovascularization, we
next examined the tumor expression level of CD31. As shown
in Fig. 2, the CD31-positive vessels in the tumors of either
G2 or G3 were moderately fewer than those in the control
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group; i.e., the results were similar to those of the pancreatic
tumor development. The combination treatment of GEM plus
Lo significantly attenuated the CD31-positive vessels in the
tumor. We employed computer-assisted image analysis
techniques to perform semi-quantification of neovasculari-
zation in the tumor as described previously (25). The semi-
quantitative analysis revealed that the CD31-positive vessels
in G2 or G3 were suppressed as compared to the control
group (p<0.05), and the combination treatment of GEM and
Lo (G4) exerted a more potent inhibition of CD31-positive
vessels in the tumor as compared to G2 and G3 (p<0.05)
(Fig. 3).
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Figure 1. Effects of GEM and Lo on the pancreatic tumor development. Single treatment with either GEM (50 mg/kg/twice a week, G2) or Lo (30 mg/kg/day,
G3) showed moderate inhibitory effect on the pancreatic tumor development as compared to the control group (G1) (P<0.05). The inhibitory effects in G2 and
G3 were almost of similar magnitude. The mice treated with GEM plus Lo (G4) showed a significant inhibition in the tumor volume as compared with those
of G2 or G3 and G1 (p<0.05 and <0.01, respectively). The tumor volume was determined at the indicated time-points from day 21 (the mean tumor volume was
200 mm3). Each point represents the mean ± SD (n=10). Single and double asterisk indicate statistically significant differences between the indicated experi-
mental groups (p<0.05 and <0.01, respectively). The white arrow indicates the time-point at which the combination treatment of GEM plus Lo started (day 49).
Figure 2. Immunohistochemical analysis of the CD31 expression in the tumor. Tumor vascularization was visualized by immunostaining of the CD31
vascular endothelial adhesion protein. (A), The control untreated group. (B), GEM-treated group. (C), Lo-treated group. (D), GEM and Lo combination-
treated group. The original magnifications are x40.
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Expression of VEGF in the tumor. To elucidate whether the
suppressive effects of GEM and Lo on neovascularization
were accompanied with inhibition of VEGF or not, we
examined the VEGF expression of the tumor. As shown in
Fig. 4, the VEGF expression in the tumor was suppressed by
single agent treatment with GEM or Lo (p<0.05), and the
combination treatment with GEM and Lo exerted a much
stronger inhibition of VEGF as compared with either single
agent (p<0.05). We also found the mRNA expression of
VEGF in the tumor was suppressed by treatment with GEM
and Lo (data not shown). The inhibitory effects of GEM and
Lo on the VEGF expression were almost in parallel with
those of inhibition of neovascularization in the tumor.
Discussion
In this study, we found that the single treatment with GEM or
Lo exerted a modest inhibitory effect on the pancreatic tumor
development along with suppression of VEGF-mediated
angiogenesis, and the combination treatment of both agents
exerted a more potent inhibitory effect as compared with
either single agent. Therapies targeting the tumor vessels have
proven very successful for cancer treatment in the experi-
mental models (26). However, some recent studies have
suggested that a treatment using single anti-angiogenic agent
may not be sufficient to completely inhibit tumor angio-
genesis. As such, the use of anti-angiogenic agents as mono-
therapy in treating the patients with advanced cancer has
not yet shown any significant efficacy (15,27). Significant
compensatory up-regulation of several pro-angiogenic factors
was observed after treatment with a single angiostatic agent.
In contrast, treatment with combination angiostatic therapy
significantly reduced the compensatory up-regulation
(15,28). Pre-clinical evidence indicated that combining anti-
angiogenic agents with a conventional chemotherapeutic
agent therapy results in additive or even synergistic anti-
tumoral effect (12,29,30). Several studies have shown that
the combination of newly developed anti-angiogenic agents
(DC101, SU5416 and TNP-470) and GEM inhibited the tumor
growth and angiogenesis synergistically in pancreatic cancer
experimental models (31). Although several anti-angiogenic
agents have already been employed in the clinical practice,
these newly developed agents frequently induce severe side
effects such as perforation of the gastrointestinal tract and
hand-foot syndrome (32,33). In the current study, we
employed Lo as an anti-angiogenic agent. Lo is widely used
currently without serious side effects in more than 100
countries, and its safety of administration to the patients with
hypertension has already been proven. A noteworthy finding
in this study was that the inhibitory effect of GEM and Lo
could be observed at clinically comparable low doses of both
agents. Furthermore, Lo was added after the tumor kept
growing under the condition of GEM treatment. Since
pancreatic tumors frequently exert drug resistance with single
treatment of GEM in the clinical practice, we assume that the
experimental condition in the current study was very similar
to that of the patients with advanced GEM-resistant
pancreatic cancer.
We observed that the inhibitory effects of GEM and Lo
were associated with suppression of neovascularization and
VEGF in the tumor. Of the numerous identified pro-angiogenic
factors, VEGF appears to be a key factor in tumor angio-
genesis, and VEGF is known to be a survival factor for the
EC (24,34). In the pancreatic tumor, VEGF was found to
play an important role in supporting the aberrant growth of
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Figure 3. Semi-quantitative analysis of CD31-immunopositive vessels. The
length of CD31-positive vessels in the tumor was measured by an image
analysis system as described in Materials and methods section. The CD31-
positive vessels in the tumors of either G2 or G3 were moderately fewer
than those in the control group, and these results matched those of the
pancreatic tumor development. The combination treatment of GEM plus Lo
significantly attenuated the CD31-positive vessels in the tumor. The data
represent the mean ± SD (n=5). Single and double asterisk indicate statis-
tically significant differences between the indicated experimental groups
(p<0.05 and <0.01, respectively). C, the untreated control group. G and L,
GEM- and Lo-treated group, respectively. G+L, GEM and Lo combination-
treated group.
Figure 4. Effects of GEM and Lo on the VEGF expression in the tumor. The
VEGF protein level was measured by ELISA as described in Materials and
methods section. The VEGF expression in the tumor was suppressed by
single agent treatment with GEM or Lo, and the combination treatment with
GEM and Lo exerted a much stronger inhibition of VEGF as compared with
either single agent. The data represent the mean ± SD (n=5). Asterisk indicates
statistically significant difference as compared to the control group (p<0.05).
C, the untreated control group. G and L, GEM- and Lo-treated group,
respectively. G+L, GEM and Lo combination-treated group.
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the tumor through maintaining its blood supply (35-37). Also,
high levels of VEGF correlated with lymph node metastasis
and poor prognosis in the patients with pancreatic cancer
(38). The VEGF gene expression is regulated by several
factors, including AT-II (18). Numerous tissues, including the
pancreas (39-41), possess their own AT-II-generating systems
that may finely tune specific function via paracrine/autocrine
actions (42,43). In pancreatic tumor cells, AT-II is a potent
stimulator of the VEGF expression through AT1-R, and Lo
suppressed the VEGF production in pancreatic tumor cell
lines in a dose-dependent manner in vitro (18). Collectively,
the suppressive effect of Lo on the VEGF expression in the
tumor was likely mediated through both paracrine/autocrine
mechanisms.
Similarly, GEM may also exert anti-tumoral effect through
paracrine/autocrine mechanisms. Classically, GEM shows a
marked anti-tumoral effect as a result of its cytotoxic action
on the cancer cells (44). In addition to this cytotoxic activity,
anti-angiogenic effect of GEM has recently been detected
(11,45). It has been reported that the EC were more sensi-
tive to GEM than the pancreatic tumor cells in vitro, and
that GEM inhibited neovascularization of the human
pancreatic tumor in nude mice at very low-dose metronomic
schedule (11). Taken together, it could be possible that co-
ordination of these different biological activities of GEM
and Lo via paracrine/autocrine mechanisms resulted in the
in vivo combination marked tumoricidial effect. Further
studies are required to elucidate the exact mechanism.
In summary, we have shown here that the combination
treatment with GEM and Lo significantly inhibited the
pancreatic tumor development along with suppression of
VEGF-mediated neovascularization even after the tumor
was fully established. Since both agents are currently widely
used in the clinical practice, this combination regimen may
represent a potential new therapeutic strategy for pancreatic
cancer.
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